Carbamazepine — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	4-8 mg/kg	q8h	Duration: Long-term; adjust based on therapeutic drug monitoring Notes: Start at low end and titrate up. Monitor plasma levels (target 4-12 µg/mL). Autoinduction may require dose adjustments after 2-4 weeks.
Cat	PO	2-5 mg/kg	q12h	Duration: Long-term; adjust based on response Notes: Cats may be more sensitive to adverse effects. Use with caution and monitor liver enzymes.
Horse	PO	5-10 mg/kg	q12h	Duration: Variable; not well established Notes: Limited data; use with caution.
Rabbit	PO	10-20 mg/kg	q8-12h	Duration: Variable; not well established Notes: Limited data; use with caution.

Clinical Indications & Species Uses

General Indications

Adjunctive therapy for seizures
Neuropathic pain management

Dog (Canine)

Adjunctive therapy for refractory epilepsy
Neuropathic pain (e.g., trigeminal neuralgia, chronic pain)
Behavioral disorders (e.g., aggression, anxiety) - off-label

Cat (Feline)

Adjunctive therapy for refractory epilepsy
Neuropathic pain (e.g., feline hyperesthesia syndrome, neuropathic pain) - off-label

Pharmacology & Mechanism of Action

Drug Class: Anticonvulsant | Pharmacological Group: Dibenzazepine derivative

Mechanism of Action: Carbamazepine primarily acts by blocking voltage-gated sodium channels in a use-dependent manner, stabilizing the inactivated state and reducing high-frequency neuronal firing. It also enhances the activity of GABA receptors, inhibits glutamate release, and modulates calcium and potassium channels. These effects collectively reduce neuronal excitability and seizure propagation.

Pharmacodynamics: Carbamazepine has anticonvulsant, antineuralgic, and mood-stabilizing properties. It reduces the release of excitatory neurotransmitters and stabilizes neuronal membranes. In veterinary patients, it is used for seizure control, particularly for refractory epilepsy, and for neuropathic pain management. Its efficacy varies among species due to differences in metabolism and receptor sensitivity.

⚡ Pharmacokinetics Summary

Absorption: Carbamazepine is well absorbed after oral administration, but absorption can be slow and variable. Peak plasma concentrations occur within 4-8 hours in dogs and cats. Food may increase absorption.

Distribution: Carbamazepine is widely distributed throughout the body, with a volume of distribution of approximately 1-2 L/kg. It crosses the blood-brain barrier and placenta, and is excreted in milk. Protein binding is approximately 70-80% in dogs.

Metabolism: Carbamazepine is extensively metabolized in the liver, primarily by cytochrome P450 enzymes (CYP3A4 in humans, but species-specific isoenzymes). The major metabolite is carbamazepine-10,11-epoxide, which is pharmacologically active. Carbamazepine induces its own metabolism (autoinduction), leading to decreased plasma concentrations over time.

Excretion: Carbamazepine and its metabolites are excreted primarily in the urine (about 70%) and feces (about 30%). Less than 2% is excreted unchanged. Biliary excretion and enterohepatic recirculation may occur.

Half-Life: Dog: 1.5-2 hours (initial), 4-8 hours (after autoinduction); Cat: 2-4 hours; Horse: 1-2 hours; Rabbit: 2-4 hours.

Bioavailability: Oral bioavailability is approximately 70-90% in dogs and cats, but may be lower in other species.

Protein Binding: 70-80% in dogs; 75-80% in cats; 70% in horses.

Available Formulations & Strengths

Oral Tablet 200 mg, 300 mg, 400 mg (PO)

Oral Suspension 100 mg/5 mL (PO)

Extended-release Tablet 100 mg, 200 mg, 400 mg (PO)

Injectable Solution Not commonly available; may be compounded (IV)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to carbamazepine or tricyclic antidepressants
Concurrent use of MAO inhibitors (within 14 days)
Severe hepatic disease
Severe bone marrow depression
Known history of blood dyscrasias

Warnings & Clinical Precautions:

Use with caution in patients with cardiac disease, hepatic or renal impairment, or glaucoma.
May cause drowsiness and ataxia; monitor for sedation.
Monitor complete blood count and liver enzymes periodically.
Autoinduction may lead to decreased efficacy; adjust dose accordingly.
Abrupt withdrawal may precipitate seizures; taper gradually.
Use in pregnant or lactating animals only if benefits outweigh risks.
May cause false-positive urine glucose tests.

Adverse Effects & Reactions

Common:

Sedation
Ataxia
Vomiting
Diarrhea
Anorexia
Polyuria/Polydipsia

Serious / Severe:

Bone marrow suppression (leukopenia, thrombocytopenia, anemia)
Hepatotoxicity
Stevens-Johnson syndrome
Cardiac arrhythmias
Pancreatitis

Rare:

Hyponatremia
SIADH
Hypothyroidism
Renal toxicity
Blood dyscrasias

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Phenobarbital	Decreases carbamazepine levels; may increase epoxide metabolite levels.	Moderate
Phenytoin	Decreases carbamazepine levels; increases phenytoin levels.	Moderate
Cimetidine	Increases carbamazepine levels by inhibiting metabolism.	Moderate
Erythromycin	Increases carbamazepine levels by inhibiting metabolism.	Moderate
Fluoxetine	Increases carbamazepine levels; risk of serotonin syndrome.	High
Grapefruit juice	Increases carbamazepine levels.	Mild

Overdose & Toxicity Management

Signs of Toxicity:

Ataxia
Drowsiness
Coma
Seizures
Respiratory depression
Cardiac arrhythmias
Hypotension
Nystagmus
Hyperreflexia

Emergency Treatment Protocol: Induce vomiting if recent ingestion and patient is conscious. Administer activated charcoal. Provide symptomatic and supportive care: IV fluids, respiratory support, cardiac monitoring. For severe toxicity, consider hemodialysis or hemoperfusion. No specific antidote.

Food Animal Withdrawal Times

Not approved for food animals; no withdrawal times established. Use in food animals is prohibited or strictly regulated.

Storage, Handling & Regulatory Information

Storage Temperature: Store at room temperature (20-25°C)

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light and moisture. Keep in tight container.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use only.

Extra-Label (Off-Label) Use: In the US, extra-label use in animals is permitted under AMDUCA, but only by or on the order of a veterinarian within a valid VCPR. Not approved for veterinary species; use is off-label.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Carbamazepine is used as an adjunctive anticonvulsant in dogs and cats, particularly for refractory epilepsy. It is also used for neuropathic pain. Due to its short half-life and autoinduction, therapeutic drug monitoring is recommended. Adverse effects include sedation, ataxia, and potential hepatotoxicity and bone marrow suppression. It is not a first-line anticonvulsant in veterinary medicine; phenobarbital and potassium bromide are more commonly used. Use with caution and monitor CBC and liver enzymes regularly.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)